title: [Preliminary clinical evaluations of bevacizumab for recurrent malignant glioma in Chinese patients].
abstract: OBJECTIVE
  To explore the clinical efficacies of bevacizumab (BEV) for high-grade glioma (HGG) in Chinese patients and evaluate its profiles of adverse events and usage safety.
  
  
  METHODS
  A total of 15 HGG cases, including glioblastoma multiform (GBM) (n = 12) and anaplastic astrocytoma (AA) (n = 3), were selected to receive the treatments of BEV (10 mg/kg, q2w) and temozolomide (TMZ, 150 mg/m(2), 5 d/28 d). Their radiological responses, clinical status, progression-free survival (PFS) and overall survival (OS) were evaluated. Also their adverse events and severity were recorded and analyzed.
  
  
  RESULTS
  According to the RANO criteria, during the short period (<3 months), 11 cases had significant radiological and clinical responses. However, only 4 cases responded during a follow-up period of beyond 3 months. Three cases had retrogression after BEV chemotherapy. At 6 months post-treatment, 8 cases (53.3%) survived without lesion progression and the median PFS was 8 ± 5 months. During a longer follow-up (>6 months), 8 patients had tumor retrogression, including 5 deaths. The median overall survival period was 24 ± 10 months. The adverse events included hypertension (n = 2), wound-healing complication (n = 1), vomiting (n = 2) and cerebro-spinal fluid leakage (n = 1). All complications were cured by activate supportive measures.
  
  
  CONCLUSIONS
  After BEV treatment, most patients obtain more significant short-term responses with good toleration. For re-operative cases, the usage of BEV should be deferred to one month post-operation so as to avoid the occurrence of wound-healing complications.
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Yuntao
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Email: sjwk_songtao@live.cn.
authors.forename: Songtao
authors.initials: S
authors.lastname: Qi
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Ouyang
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Yanyi
authors.initials: Y
authors.lastname: Yin
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Shi
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Qiu
authors.affiliation: Department of neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Mo
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab